Oana-Diana Persa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Oana-Diana Persa has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
Cornelia Mauch
Department of Dermatology and Venereology University Hospital Cologne Cologne Germany
26 shared publications- Yannick Foerster
Department of Dermatology TUM School of Medicine and Health Munich Germany
20 shared publications Alexander Quaas
19 shared publicationsChristiane J. Bruns
19 shared publications- Christine Kurschat
Department II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
19 shared publications Claire Aguilar
19 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (8) , 1052-1062
Komplette Lymphknotendissektion versus selektive Lymphknotenexstirpation bei Melanompatienten mit nodaler Makrometastasierung und adjuvanter Systemtherapie
Zusammenfassung: Hintergrund und Zielsetzung: Die komplette Lymphknotendissektion (CLND) gilt als Standardbehandlung bei Melanompatienten mit regionalen Lymphknotenmakrometastasen. Es fehlt jedoch an Evidenz bezüglich des chirurgischen Vorgehens im Kontext adjuvanter Systemtherapien. Patienten und Methodik: Diese retrospektive multizentrische Studie schloss Melanompatienten im Stadium IIIB–D mit nodaler Makrometastasierung ein, die vor einer adjuvanten Therapie eine CLND oder selektive Lymphknotenexstirpation (LNE) erhalten hatten. CLND und LNE wurden bezüglich des rezidivfreien Überlebens (RFS), des Lymphknotenmetastasen‐freien Überlebens (NFS) und des Gesamtüberlebens (OS) verglichen. Ergebnisse: 320 Patienten wurden eingeschlossen (medianes Alter 62 Jahre; 55,5 % Männer). Die Patienten erhielten entweder eine PD‐1‐Monotherapie (77,8 %), eine zielgerichtete Therapie (21,3 %) oder beides sequenziell (0,9 %) sowie eine adjuvante Strahlentherapie in 40,9 % der Fälle. RFS und OS unterschieden sich nicht signifikant nach CLND oder LNE, während das NFS nach CLND signifikant verlängert war (HR 0,3917; p = 0,005). Unter Berücksichtigung von Risikofaktoren mittels multivariater Cox‐Regression zeigte sich ein verlängertes RFS für CLND gegenüber LNE (HR 0,676; p = 0,04), aber kein Vorteil im OS. Die Komplikationsrate war in der CLND‐Gruppe signifikant erhöht. Schlussfolgerungen: Die CLND zeigte keinen Gesamtüberlebensvorteil im Vergleich zur LNE, obwohl die lokale Kontrolle verbessert wurde. Die Durchführung einer CLND kann im Kontext adjuvanter Therapien empfohlen werden, jedoch sollte das erhöhte Risiko für Komplikationen bedacht werden.
- 4 August 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (8) , 1052-1062
Open AccessKomplette Lymphknotendissektion versus selektive Lymphknotenexstirpation bei Melanompatienten mit nodaler Makrometastasierung und adjuvanter Systemtherapie
Zusammenfassung: Hintergrund und Zielsetzung: Die komplette Lymphknotendissektion (CLND) gilt als Standardbehandlung bei Melanompatienten mit regionalen Lymphknotenmakrometastasen. Es fehlt jedoch an Evidenz bezüglich des chirurgischen Vorgehens im Kontext adjuvanter Systemtherapien. Patienten und Methodik: Diese retrospektive multizentrische Studie schloss Melanompatienten im Stadium IIIB–D mit nodaler Makrometastasierung ein, die vor einer adjuvanten Therapie eine CLND oder selektive Lymphknotenexstirpation (LNE) erhalten hatten. CLND und LNE wurden bezüglich des rezidivfreien Überlebens (RFS), des Lymphknotenmetastasen‐freien Überlebens (NFS) und des Gesamtüberlebens (OS) verglichen. Ergebnisse: 320 Patienten wurden eingeschlossen (medianes Alter 62 Jahre; 55,5 % Männer). Die Patienten erhielten entweder eine PD‐1‐Monotherapie (77,8 %), eine zielgerichtete Therapie (21,3 %) oder beides sequenziell (0,9 %) sowie eine adjuvante Strahlentherapie in 40,9 % der Fälle. RFS und OS unterschieden sich nicht signifikant nach CLND oder LNE, während das NFS nach CLND signifikant verlängert war (HR 0,3917; p = 0,005). Unter Berücksichtigung von Risikofaktoren mittels multivariater Cox‐Regression zeigte sich ein verlängertes RFS für CLND gegenüber LNE (HR 0,676; p = 0,04), aber kein Vorteil im OS. Die Komplikationsrate war in der CLND‐Gruppe signifikant erhöht. Schlussfolgerungen: Die CLND zeigte keinen Gesamtüberlebensvorteil im Vergleich zur LNE, obwohl die lokale Kontrolle verbessert wurde. Die Durchführung einer CLND kann im Kontext adjuvanter Therapien empfohlen werden, jedoch sollte das erhöhte Risiko für Komplikationen bedacht werden.
- Open Access
- 30 March 2026
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (3) , 1023-1025
Unusual Cutaneous and Lymphatic Findings in an Adult Patient
- 30 March 2026
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (3) , 1023-1025
Open AccessUnusual Cutaneous and Lymphatic Findings in an Adult Patient
- Open Access
- 21 January 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (8) , 1052-1061
Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapy
Summary: Background and Objectives: Complete lymph node dissection (CLND) is the standard of care in patients with regional nodal melanoma macrometastasis. However, evidence on surgical procedures in the era of adjuvant systemic therapies is lacking. Patients and Methods: This retrospective multi‐center study included stage IIIB–D melanoma patients with nodal macrometastasis undergoing CLND or selective lymph node extirpation (LNE) prior to adjuvant therapy. CLND and LNE were compared regarding recurrence‐free survival (RFS), nodal metastasis‐free survival (NFS) and overall survival (OS). Results: 320 melanoma patients were included (median age 62; 55.5% male). Patients received PD‐1 monotherapy (77.8%), targeted therapy (21.3%) or both sequentially (0.9%), as well as adjuvant radiotherapy in 40.9%. RFS and OS did not differ significantly between patients receiving CLND or LNE, while NFS was significantly prolonged following CLND (HR 0.3917; p = 0.005). After adjustment for risk factors by multivariate Cox regression, a prolonged RFS for CLND vs. LNE was found (HR 0.676; p = 0.04), but no benefit for OS. The rate of complications was significantly higher in the CLND group. Conclusions: CLND showed no OS benefit compared to LNE, while local control was improved. CLND can be recommended in the context of adjuvant therapies, however, the increased rate of complications should be considered.
- 21 January 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (8) , 1052-1061
Open AccessComplete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapy
Summary: Background and Objectives: Complete lymph node dissection (CLND) is the standard of care in patients with regional nodal melanoma macrometastasis. However, evidence on surgical procedures in the era of adjuvant systemic therapies is lacking. Patients and Methods: This retrospective multi‐center study included stage IIIB–D melanoma patients with nodal macrometastasis undergoing CLND or selective lymph node extirpation (LNE) prior to adjuvant therapy. CLND and LNE were compared regarding recurrence‐free survival (RFS), nodal metastasis‐free survival (NFS) and overall survival (OS). Results: 320 melanoma patients were included (median age 62; 55.5% male). Patients received PD‐1 monotherapy (77.8%), targeted therapy (21.3%) or both sequentially (0.9%), as well as adjuvant radiotherapy in 40.9%. RFS and OS did not differ significantly between patients receiving CLND or LNE, while NFS was significantly prolonged following CLND (HR 0.3917; p = 0.005). After adjustment for risk factors by multivariate Cox regression, a prolonged RFS for CLND vs. LNE was found (HR 0.676; p = 0.04), but no benefit for OS. The rate of complications was significantly higher in the CLND group. Conclusions: CLND showed no OS benefit compared to LNE, while local control was improved. CLND can be recommended in the context of adjuvant therapies, however, the increased rate of complications should be considered.
- Open Access
- 17 January 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (5) , 952-962
Sirolimus for Secondary Prevention of Cutaneous Squamous Cell Carcinoma in Kidney Transplant Recipients: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Kidney transplant recipients (KTRs) are at increased risk of developing cutaneous squamous cell carcinoma (cSCC), particularly when treated with calcineurin inhibitors (CNI), which are strongly associated with tumorigenesis. In contrast, mTOR inhibitors such as sirolimus have demonstrated antitumor activity, but their role in secondary prevention of cSCC remains unclear. We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) to evaluate the impact of switching from a CNI‐based to an mTOR inhibitor‐based immunosuppressive regimen on the incidence of cSCC in KTRs with prior cSCC. MEDLINE, EMBASE, CENTRAL, and trial registries were searched through June 2025. Incidence rate ratios (IRRs) for cSCC and risk ratios (RRs) for adverse events (AEs) were pooled using a random‐effects model. Risk of bias was assessed with Cochrane RoB2. The study was registered in PROSPERO prior to data extraction (CRD42024583966). The study was unfunded. Four RCTs (393 patients) were included. Sirolimus significantly reduced 2‐year cSCC incidence (IRR 0.51, 95% CI 0.39–0.67). However, discontinuation was more frequent (RR 8.60, 95% CI 1.95–37.93) due to AEs. No significant differences in mortality or graft rejection were found. Certainty of evidence was high for cSCC incidence and low for adverse events due to heterogeneity and selective reporting. In conclusion, sirolimus reduces secondary cSCC risk but increases AEs; patient selection and monitoring are essential. Trial Registration: PROSPERO number: CRD42024583966
- 17 January 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (5) , 952-962
Open AccessSirolimus for Secondary Prevention of Cutaneous Squamous Cell Carcinoma in Kidney Transplant Recipients: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Kidney transplant recipients (KTRs) are at increased risk of developing cutaneous squamous cell carcinoma (cSCC), particularly when treated with calcineurin inhibitors (CNI), which are strongly associated with tumorigenesis. In contrast, mTOR inhibitors such as sirolimus have demonstrated antitumor activity, but their role in secondary prevention of cSCC remains unclear. We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) to evaluate the impact of switching from a CNI‐based to an mTOR inhibitor‐based immunosuppressive regimen on the incidence of cSCC in KTRs with prior cSCC. MEDLINE, EMBASE, CENTRAL, and trial registries were searched through June 2025. Incidence rate ratios (IRRs) for cSCC and risk ratios (RRs) for adverse events (AEs) were pooled using a random‐effects model. Risk of bias was assessed with Cochrane RoB2. The study was registered in PROSPERO prior to data extraction (CRD42024583966). The study was unfunded. Four RCTs (393 patients) were included. Sirolimus significantly reduced 2‐year cSCC incidence (IRR 0.51, 95% CI 0.39–0.67). However, discontinuation was more frequent (RR 8.60, 95% CI 1.95–37.93) due to AEs. No significant differences in mortality or graft rejection were found. Certainty of evidence was high for cSCC incidence and low for adverse events due to heterogeneity and selective reporting. In conclusion, sirolimus reduces secondary cSCC risk but increases AEs; patient selection and monitoring are essential. Trial Registration: PROSPERO number: CRD42024583966
- Open Access
- 7 December 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (12) , e70185
High ROR1 Expression Is Associated With Poor Differentiation and Perineural Invasion in Cutaneous Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma (cSCC) is a common type of skin cancer, predominantly affecting elderly and immunosuppressed patients. Despite recent therapeutic advances, including the introduction of immune checkpoint inhibitors, outcomes for patients with metastatic or recurrent disease remain poor, underscoring the need for new therapeutic approaches and reliable biomarkers to identify patients at high risk of progression. In this context, receptor tyrosine kinase‐like orphan receptor 1 (ROR1), previously associated with poor prognosis and targeted therapeutically in other malignancies, has not yet been investigated in cSCC. This study aimed to evaluate ROR1 expression in cSCC and investigate its potential role as a biomarker for tumour aggressiveness. ROR1 expression was analysed via immunofluorescence in a tissue microarray of 360 cSCC samples from a biobank cohort at the University Hospital Cologne. Fluorescence intensity was quantified and correlated with clinicopathologic features and patient outcomes. High ROR1 expression was detected in 42.5% of samples, predominantly localised at tumour invasive fronts. Elevated ROR1 levels were significantly associated with poor tumour differentiation ( p < 0.001), lymph node metastasis ( p = 0.007), and perineural invasion ( p = 0.005). Although higher ROR1 expression correlated with worse progression‐free and metastasis‐free survival, these differences did not reach statistical significance. In conclusion, this study identifies ROR1 as a novel marker of aggressive cSCC, linked to poor differentiation, lymphatic spread and perineural invasion. ROR1 holds potential both as a prognostic biomarker and as a therapeutic target, encouraging future exploration of ROR1‐directed therapies in advanced cSCC.
- 7 December 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (12) , e70185
Open AccessHigh ROR1 Expression Is Associated With Poor Differentiation and Perineural Invasion in Cutaneous Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma (cSCC) is a common type of skin cancer, predominantly affecting elderly and immunosuppressed patients. Despite recent therapeutic advances, including the introduction of immune checkpoint inhibitors, outcomes for patients with metastatic or recurrent disease remain poor, underscoring the need for new therapeutic approaches and reliable biomarkers to identify patients at high risk of progression. In this context, receptor tyrosine kinase‐like orphan receptor 1 (ROR1), previously associated with poor prognosis and targeted therapeutically in other malignancies, has not yet been investigated in cSCC. This study aimed to evaluate ROR1 expression in cSCC and investigate its potential role as a biomarker for tumour aggressiveness. ROR1 expression was analysed via immunofluorescence in a tissue microarray of 360 cSCC samples from a biobank cohort at the University Hospital Cologne. Fluorescence intensity was quantified and correlated with clinicopathologic features and patient outcomes. High ROR1 expression was detected in 42.5% of samples, predominantly localised at tumour invasive fronts. Elevated ROR1 levels were significantly associated with poor tumour differentiation ( p < 0.001), lymph node metastasis ( p = 0.007), and perineural invasion ( p = 0.005). Although higher ROR1 expression correlated with worse progression‐free and metastasis‐free survival, these differences did not reach statistical significance. In conclusion, this study identifies ROR1 as a novel marker of aggressive cSCC, linked to poor differentiation, lymphatic spread and perineural invasion. ROR1 holds potential both as a prognostic biomarker and as a therapeutic target, encouraging future exploration of ROR1‐directed therapies in advanced cSCC.
- Open Access
- 14 November 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (11) , 1373-1386
Therapien des Morbus Bowen: Systematisches Review und Netzwerk‐Metaanalyse randomisierter kontrollierter Studien
Zusammenfassung: Morbus Bowen (MB) ist eine intraepidermale bösartige Neubildung, die zu einem invasiven Plattenepithelkarzinom der Haut führen kann. Bisher existiert keine Studie, die Therapieoptionen aus randomisierten kontrollierten Studien (RCT) miteinander verglichen hat. In dieser Arbeit wurden Daten aus verfügbaren RCT extrahiert, um läsionsspezifische Heilungsraten und kosmetische Ergebnisse mit Placebo zu vergleichen. Wir durchsuchten MEDLINE, EMBASE, CENTRAL und Studienregister bis 30. September 2024, und schlossen neun Studien mit 672 Patienten und 844 Läsionen ein. Die Therapieoptionen, welche mithilfe einer Netzwerk‐Metaanalyse verglichen wurden, umfassten: Exzision, Imiquimod, photodynamische Therapie (PDT), Laserablation (LA), lasergestützte PDT (LA‐PDT), Kryotherapie und 5‐Fluoruracil (5‐FU). Das Verzerrungsrisiko wurde mithilfe des überarbeiteten Cochrane risk‐of‐bias Tool evaluiert. Die Studie wurde in PROSPERO registriert (CRD42024583966). Alle Therapieoptionen zeigten bessere läsionsspezifische Heilungsraten als Placebo. Bezüglich der initialen Heilungsrate zeigte LA‐PDT die besten Ergebnisse, gefolgt von Exzision und LA. Die Exzision zeigte die besten Ergebnisse bezüglich der langfristigen Heilungsrate, gefolgt von LA‐PDT und PDT. LA‐PDT und 5‐FU hatten das beste, die Exzision das schlechteste kosmetische Ergebnis. Limitationen umfassen ein moderates bis hohes Verzerrungsrisiko sowie Heterogenität der Einzelstudien. Unsere Ergebnisse unterstützen die klinische Entscheidungsfindung, wobei sich LA‐PDT und PDT als effektive Optionen bei guten kosmetischen Ergebnissen erwiesen haben. Die Exzision zeigte jedoch die besten langfrisigen Heilungsraten.
- 14 November 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (11) , 1373-1386
Open AccessTherapien des Morbus Bowen: Systematisches Review und Netzwerk‐Metaanalyse randomisierter kontrollierter Studien
Zusammenfassung: Morbus Bowen (MB) ist eine intraepidermale bösartige Neubildung, die zu einem invasiven Plattenepithelkarzinom der Haut führen kann. Bisher existiert keine Studie, die Therapieoptionen aus randomisierten kontrollierten Studien (RCT) miteinander verglichen hat. In dieser Arbeit wurden Daten aus verfügbaren RCT extrahiert, um läsionsspezifische Heilungsraten und kosmetische Ergebnisse mit Placebo zu vergleichen. Wir durchsuchten MEDLINE, EMBASE, CENTRAL und Studienregister bis 30. September 2024, und schlossen neun Studien mit 672 Patienten und 844 Läsionen ein. Die Therapieoptionen, welche mithilfe einer Netzwerk‐Metaanalyse verglichen wurden, umfassten: Exzision, Imiquimod, photodynamische Therapie (PDT), Laserablation (LA), lasergestützte PDT (LA‐PDT), Kryotherapie und 5‐Fluoruracil (5‐FU). Das Verzerrungsrisiko wurde mithilfe des überarbeiteten Cochrane risk‐of‐bias Tool evaluiert. Die Studie wurde in PROSPERO registriert (CRD42024583966). Alle Therapieoptionen zeigten bessere läsionsspezifische Heilungsraten als Placebo. Bezüglich der initialen Heilungsrate zeigte LA‐PDT die besten Ergebnisse, gefolgt von Exzision und LA. Die Exzision zeigte die besten Ergebnisse bezüglich der langfristigen Heilungsrate, gefolgt von LA‐PDT und PDT. LA‐PDT und 5‐FU hatten das beste, die Exzision das schlechteste kosmetische Ergebnis. Limitationen umfassen ein moderates bis hohes Verzerrungsrisiko sowie Heterogenität der Einzelstudien. Unsere Ergebnisse unterstützen die klinische Entscheidungsfindung, wobei sich LA‐PDT und PDT als effektive Optionen bei guten kosmetischen Ergebnissen erwiesen haben. Die Exzision zeigte jedoch die besten langfrisigen Heilungsraten.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Case examples and prognostic analysis.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Case examples and prognostic analysis.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Time till treatment progression and overall survival stratified by TGFBR1 expression
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Time till treatment progression and overall survival stratified by TGFBR1 expression
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Univariable Cox regression analysis of factors contributing to progression in the cessation cohort.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Univariable Cox regression analysis of factors contributing to progression in the cessation cohort.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Correlation of TGFBR1 expression and immune cell infiltrate.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Correlation of TGFBR1 expression and immune cell infiltrate.